Lentiviral vectors encoding clotting factors for gene therapy

Details Lentiviral vectors encoding clotting factors for gene therapy Lentiviral vectors encoding clotting factors for gene therapy

2002-05-14

2004-10-26

Priebe, Scott D. (Department: 1632)

Chemistry: molecular biology and microbiology

Micro-organism, tissue cell culture or enzyme using process...

Preparing compound containing saccharide radical

C435S320100, C435S455000, C435S456000, C435S465000, C424S093200, C536S024100

Reexamination Certificate

active

06808905

ABSTRACT:

TECHNICAL FIELD OF THE INVENTION
The present invention relates to gene therapy. In particular it relates to vectors for use in the preparation of recombinant lentiviruses and the use of replication-deficient lentiviral vectors to deliver a therapeutic gene to a target tissue of a subject. Suitable therapeutic genes include genes that encode clotting factors, such as factor VIII or factor IX, to treat a blood clotting disease such as hemophilia. The invention further relates to enhancers and promoters useful for tissue-specific gene therapy.
BACKGROUND OF THE INVENTION
Gene therapy generally relates to the delivery of one or more heterologous genes to a subject in order to treat a disease. Hemophilia is a genetic disease caused by a deficiency of a blood clotting factor. There are two types of X-linked bleeding disorders, hemophilia A and hemophilia B. In some cases of von Willebrand disease, the most common bleeding disorder, deficient levels of vWF result in low levels of factor VIII, mimicking hemophilia A. Hemophilia A affects about 17,000 people in the US and is caused by a deficiency in factor VIII. The incidence of hemophilia B is 1 out of 34,500 men, and it is caused by a deficiency in factor IX. Each of these diseases is an excellent theoretical candidate for gene therapy, as each has a reasonably simple molecular pathology and should be remediable by the delivery of a single gene.
Successful gene therapy for hemophilia requires both tissue specific expression, to avoid a counterproductive immune response, and sufficiently high levels of expression to generate a therapeutic response. Gene therapy directed at quiescent cells of the liver presents an additional challenge, as Park et al. teach that stable and efficient transduction of liver cells with a lentiviral vector requires cell proliferation (Park et al., 2000, Nature Genetics 24:49-52). Park et al. further teach that the injection of doses of the lentiviral vector sufficiently high to reach therapeutic levels of transgene expression in the liver produces a very high liver toxicity and a high mortality (Park et al., 2000, Blood 96(3):1173-1176).
There remains a need for successful gene therapy of quiescent cells that results in therapeutically acceptable cell transduction and that produces a therapeutic amount of protein without toxicity. There is a particular need for a safe and efficient gene therapy for hemophilia.
SUMMARY OF THE INVENTION
The invention is based on the surprising discovery that replication deficient lentiviral vectors can be used to achieve stable genetic modification of cells in vivo without vector-mediated toxicity and in the absence of target cell proliferation. The invention thus provides vectors for transgene delivery as well as methods for gene therapy using such vectors. The invention further provides promoters and enhancers useful for optimizing tissue specific transgene delivery.
The invention provides a lentiviral producer cell comprising a first nucleotide sequence comprising a gag, a pol, or gag and pol genes; a second nucleotide sequence comprising a heterologous env gene; and a third nucleotide sequence comprising a lentiviral transfer vector that comprises a gene that encodes a blood clotting factor operably linked to an expression control sequence; wherein the producer cell lacks a functional tat gene. In preferred embodiments, the blood clotting factor comprises human factor IX (hFIX) or human factor VIII (hFVIII). In one embodiment, the first, second and third nucleotide sequences are stably integrated into the genome of the lentiviral producer cell. Preferably, the lentivirus is a human immunodeficiency virus (HIV), such as HIV-1. In a preferred embodiment, the producer cell further comprises a fourth nucleotide sequence that comprises a rev gene, and/or lacks functional accessory genes vif, vpr, vpu, vpx and nef, or a combination thereof.
Typically, the expression control sequence comprises a liver specific promoter, such as mouse transthyretin (mTTR) promoter, human alpha-1-antitrypsin promoter (hAAT), human albumin minimal promoter, a human factor VIII endogenous promoter, and/or mouse albumin promoter, and/or a liver specific binding site for transcription, such as EBP, DBP, HNF1, HNF3, HNF4, HNF6, or a combination thereof Preferably, the expression control sequence comprises an Enh1 enhancer (SEQ ID NO: 10) and an mTTR promoter. Also preferred is an expression control sequence comprising an &agr;-1-microglobulin/bikunin enhancer and a human factor VIII endogenous promoter (L-F8).
The invention additionally provides set of lentiviral vectors for use in a third generation lentiviral packaging system and for production of lentiviral producer cells and recombination lentiviruses. The invention provides a lentiviral transfer vector that comprises an expression control sequence operably linked to a transgene, wherein the expression control sequence comprises a novel enhancer element, Enh1 (SEQ ID NO: 10), or a novel combination of enhancer and promoter elements, such as L-F8 or Enh1 and mTTR. The transgene is preferably a therapeutic transgene. A preferred transgene is one that encodes a blood clotting factor, such as human Factor VIII or human Factor IX. Such transgenes encoding blood clotting factors can be used in the treatment of bleeding disorders such as hemophilia. Also provided is a method of producing a lentiviral producer cell comprising transforming a cell with the set of vectors of the invention. The invention further provides a method of producing a recombinant lentivirus, and a method of delivering a transgene to a cell.


REFERENCES:
patent: 5583022 (1996-12-01), Heidmann et al.
patent: 5614404 (1997-03-01), Mazzara et al.
patent: 5650309 (1997-07-01), Wong-Staal et al.
patent: 5665577 (1997-09-01), Sodroski et al.
patent: 5681746 (1997-10-01), Bodner et al.
patent: 5686279 (1997-11-01), Finer et al.
patent: 5693508 (1997-12-01), Chang
patent: 5716613 (1998-02-01), Guber et al.
patent: 5716826 (1998-02-01), Gruber et al.
patent: 5739118 (1998-04-01), Carrano et al.
patent: 5747307 (1998-05-01), Lever et al.
patent: 5750383 (1998-05-01), Blissard et al.
patent: 5994136 (1999-11-01), Naldini et al.
patent: 6013516 (2000-01-01), Verma et al.
patent: 6165782 (2000-12-01), Naldini et al.
patent: 6207455 (2001-03-01), Chang
patent: 6221349 (2001-04-01), Couto et al.
patent: 6338953 (2002-01-01), Boyce et al.
patent: 6428953 (2002-08-01), Naldini et al.
patent: 0 759 471 (1997-02-01), None
patent: WO 98/12314 (1998-03-01), None
patent: WO 99/04026 (1999-01-01), None
patent: WO 99/31251 (1999-06-01), None
patent: WO 00/66759 (2000-11-01), None
Berkhout et al., “Tat Transactivates the Human Immunodeficiency Virus Through a Nascent RNA Target,” Cell, 1989, vol. 59: 273-282.
Blissard et al., “Location, Sequence, Transcriptional Mapping, and Temporal Expression of the gp64 Envelope Glycoprotein Gene of the Orgyia Pseudotsugata Multicapsid Nuclear Polyhedrosis Virus,” Virology, 1989, 170(2): 537-55.
Blomer et al., “Highly Efficient and Sustained Gene Transfer in Adult Neurons with a Lentivirus Vector,” Jnl. of Virology, Sep. 1997, vol. 71(9): 6641-6649.
A. Bukovsky et al., “Interaction of Human Immunodeficiency Virus-Derived Vectors with Wild-Type Virus in Transduced Cells,” Jnl. of Virology, Aug. 1999, vol. 73(8): 7087-7092.
L-J Chang et al., “Efficacy and Safety Analyses of a Recombinant Human Immunodeficiency Virus Type 1 Derived Vector System,” Gene Therapy, 1999, vol. 6: 715-728.
JM Coffin Fundamental Virology, 1996, 3rdedition (Fields et al., eds), Chapter 26, “Retroviridae. The Viruses and Their Replication,” pp. 763-843, Lipincott-Raven Publishers, Philadelphia, PA.
R.H. Costa et al., “Transcriptional Control of the Mouse Prealbumin (Transthyretin) Gene: Both Promoter Sequences and a Distinct Enhancer are Cell Specific,” Mol. Cell. Biol., 1986, 6: 4697.
M. Curran et al, “Efficient Transduction of Nondividing Cells by Optimized Feline Immunodeficieny Virus Vectors,” Mol. Ther., 2000, 1: 31-8.
T. Dull et al., “A Third Generation Lentivirus Vector with a Conditional Pac

Affiliated with

Also associated with

Rating

Lentiviral vectors encoding clotting factors for gene therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Lentiviral vectors encoding clotting factors for gene therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Lentiviral vectors encoding clotting factors for gene therapy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3307496